Recent Advancements in Tuberculosis Drug Discovery
Herausgeber: Chavda, Vivek P.; Teli, Divya M.; Chhabria, Mahesh T.
Recent Advancements in Tuberculosis Drug Discovery
Herausgeber: Chavda, Vivek P.; Teli, Divya M.; Chhabria, Mahesh T.
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Covers topics, from drug resistance to using AI to enhance treatment methods for TB. Explore TB diagnosis methods, drug resistance mechanisms in TB, and limitations in existing drugs and proposes strategies such as structural modifications, efflux pathway targeting, and host-directed therapies to overcome resistance.
Andere Kunden interessierten sich auch für
Advancements in Controlled Drug Delivery Systems348,99 €
Research Advancements in Pharmaceutical, Nutritional, and Industrial Enzymology234,99 €
Advancements in Artificial Intelligence for Dentomaxillofacial Radiology60,99 €
Advancements in Individualized Plastic and Reconstructive Surgery52,99 €
Advancements in Tumor Immunotherapy and Cancer Vaccines84,99 €
Advancements in Clinical Medicine475,99 €
Molecular Oncology: Underlying Mechanisms and Translational Advancements83,99 €-
-
-
Covers topics, from drug resistance to using AI to enhance treatment methods for TB. Explore TB diagnosis methods, drug resistance mechanisms in TB, and limitations in existing drugs and proposes strategies such as structural modifications, efflux pathway targeting, and host-directed therapies to overcome resistance.
Produktdetails
- Produktdetails
- Verlag: Apple Academic Press
- Seitenzahl: 464
- Erscheinungstermin: 2. Dezember 2025
- Englisch
- Abmessung: 260mm x 183mm x 29mm
- Gewicht: 1061g
- ISBN-13: 9781998511808
- ISBN-10: 1998511804
- Artikelnr.: 75227554
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
- Verlag: Apple Academic Press
- Seitenzahl: 464
- Erscheinungstermin: 2. Dezember 2025
- Englisch
- Abmessung: 260mm x 183mm x 29mm
- Gewicht: 1061g
- ISBN-13: 9781998511808
- ISBN-10: 1998511804
- Artikelnr.: 75227554
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
Vivek P. Chavda, MPharm, is an Assistant Professor of Pharmaceutics and Pharmaceutical Technology at the L. M. College of Pharmacy, India. He earlier served in the biologics industry in research and development with two successful regulatory filings. He has more than 250 national and international publications, nearly 20 book chapters, several books, one patent in progress as well as numerous newsletter articles to his credit. His research interests include development of biologics processes and formulations, medical device development, nano-diagnostics, long-acting parenteral formulations, and nano-vaccines. Mahesh T. Chhabria, PhD, is a Principal and Professor at the L. M. College of Pharmacy, India. He has around 70 research publications, one patent granted, and 10 patent applications to his credit. He has availed research grants of equating to nearly $1 million USD and has also received grants for setting up of the Atal Incubation Centre at the L. M. College of Pharmacy. He has supervised around nearly 150 MPharm and PhD students. His primary field of expertise revolves around medicinal chemistry and the utilization of computer-aided drug design methodologies, focusing on innovation and advancement of novel compounds targeting tuberculosis, hyperlipidemia, cancer, and COVID-19. Divya M. Teli, MPharm, is an Assistant Professor of Pharmaceutical Chemistry at L. M. College of Pharmacy, India. She has industrial experience of five years in the Department of Research and Development at o2h discovery Pvt. Ltd. Her area of interest includes synthesis of small organic heterocyclic molecules and indigenous novel route development for the synthesis of active pharmaceutical ingredients, key starting materials and drug intermediates, route scouting, computer aided-drug design, discovery and development of novel antitubercular, and anticancer and antiviral agents.
PART I: UNDERSTANDING TUBERCULOSIS (TB) AND ITS CHALLENGES 1. Tuberculosis
Drug Discovery: From Evil to Allies 2. Relationship Between Covid-19 and
Tuberculosis 3. Advancement in the Diagnosis of Tuberculosis 4. Mechanisms
of Drug Resistance in Tuberculosis and Potential Modulation Strategies
PART II: NEW FRONTIERS IN TB DRUG DISCOVERY 5. Outsmarting the Superbug: A
Look at New Targets for Tuberculosis Treatment 6. Deciphering
Antitubercular Drug Pharmacokinetics 7. Structure-Based Drug Design for
Tuberculosis PART III: SUCCESS STORIES AND EMERGING HOPE 8. The Journey of
Bedaquiline: Revolutionizing Tuberculosis Treatment 9. Delamanid and
Pretomanid: From Bench to Bedside 10. Overview of DprE1 Inhibitors and
Development of Macozinone and Other Drugs 11. Unleashing the Power Within:
Host Directed Therapies Revolutionizing Tuberculosis Treatment PART IV:
TOOLS AND TECHNOLOGIES FOR A TB-FREE FUTURE 12. Artificial Intelligence in
Tuberculosis Management 13. Novel Drug Delivery Systems for Tuberculosis
Treatment PART V: TOWARD A TB-FREE WORLD: VACCINES, BIOMARKERS, AND THE
FUTURE 14. Advances in Tuberculosis Control: Vaccines and Biomarkers 15.
Future Perspectives and Emerging Strategies in Tuberculosis Drug Discovery
Drug Discovery: From Evil to Allies 2. Relationship Between Covid-19 and
Tuberculosis 3. Advancement in the Diagnosis of Tuberculosis 4. Mechanisms
of Drug Resistance in Tuberculosis and Potential Modulation Strategies
PART II: NEW FRONTIERS IN TB DRUG DISCOVERY 5. Outsmarting the Superbug: A
Look at New Targets for Tuberculosis Treatment 6. Deciphering
Antitubercular Drug Pharmacokinetics 7. Structure-Based Drug Design for
Tuberculosis PART III: SUCCESS STORIES AND EMERGING HOPE 8. The Journey of
Bedaquiline: Revolutionizing Tuberculosis Treatment 9. Delamanid and
Pretomanid: From Bench to Bedside 10. Overview of DprE1 Inhibitors and
Development of Macozinone and Other Drugs 11. Unleashing the Power Within:
Host Directed Therapies Revolutionizing Tuberculosis Treatment PART IV:
TOOLS AND TECHNOLOGIES FOR A TB-FREE FUTURE 12. Artificial Intelligence in
Tuberculosis Management 13. Novel Drug Delivery Systems for Tuberculosis
Treatment PART V: TOWARD A TB-FREE WORLD: VACCINES, BIOMARKERS, AND THE
FUTURE 14. Advances in Tuberculosis Control: Vaccines and Biomarkers 15.
Future Perspectives and Emerging Strategies in Tuberculosis Drug Discovery
PART I: UNDERSTANDING TUBERCULOSIS (TB) AND ITS CHALLENGES 1. Tuberculosis
Drug Discovery: From Evil to Allies 2. Relationship Between Covid-19 and
Tuberculosis 3. Advancement in the Diagnosis of Tuberculosis 4. Mechanisms
of Drug Resistance in Tuberculosis and Potential Modulation Strategies
PART II: NEW FRONTIERS IN TB DRUG DISCOVERY 5. Outsmarting the Superbug: A
Look at New Targets for Tuberculosis Treatment 6. Deciphering
Antitubercular Drug Pharmacokinetics 7. Structure-Based Drug Design for
Tuberculosis PART III: SUCCESS STORIES AND EMERGING HOPE 8. The Journey of
Bedaquiline: Revolutionizing Tuberculosis Treatment 9. Delamanid and
Pretomanid: From Bench to Bedside 10. Overview of DprE1 Inhibitors and
Development of Macozinone and Other Drugs 11. Unleashing the Power Within:
Host Directed Therapies Revolutionizing Tuberculosis Treatment PART IV:
TOOLS AND TECHNOLOGIES FOR A TB-FREE FUTURE 12. Artificial Intelligence in
Tuberculosis Management 13. Novel Drug Delivery Systems for Tuberculosis
Treatment PART V: TOWARD A TB-FREE WORLD: VACCINES, BIOMARKERS, AND THE
FUTURE 14. Advances in Tuberculosis Control: Vaccines and Biomarkers 15.
Future Perspectives and Emerging Strategies in Tuberculosis Drug Discovery
Drug Discovery: From Evil to Allies 2. Relationship Between Covid-19 and
Tuberculosis 3. Advancement in the Diagnosis of Tuberculosis 4. Mechanisms
of Drug Resistance in Tuberculosis and Potential Modulation Strategies
PART II: NEW FRONTIERS IN TB DRUG DISCOVERY 5. Outsmarting the Superbug: A
Look at New Targets for Tuberculosis Treatment 6. Deciphering
Antitubercular Drug Pharmacokinetics 7. Structure-Based Drug Design for
Tuberculosis PART III: SUCCESS STORIES AND EMERGING HOPE 8. The Journey of
Bedaquiline: Revolutionizing Tuberculosis Treatment 9. Delamanid and
Pretomanid: From Bench to Bedside 10. Overview of DprE1 Inhibitors and
Development of Macozinone and Other Drugs 11. Unleashing the Power Within:
Host Directed Therapies Revolutionizing Tuberculosis Treatment PART IV:
TOOLS AND TECHNOLOGIES FOR A TB-FREE FUTURE 12. Artificial Intelligence in
Tuberculosis Management 13. Novel Drug Delivery Systems for Tuberculosis
Treatment PART V: TOWARD A TB-FREE WORLD: VACCINES, BIOMARKERS, AND THE
FUTURE 14. Advances in Tuberculosis Control: Vaccines and Biomarkers 15.
Future Perspectives and Emerging Strategies in Tuberculosis Drug Discovery







